Pulse Biosciences Announces Positive Results from Its First Study Evaluating a Clinical Target at Major Scientific Meeting
  • Multi-center study with leading researchers shows positive results for treatment of seborrheic keratosis lesions with a single treatment of non-thermal Nano-Pulse Stimulation (NPS)
  • Dose-response study of clinical and histological effects of NPS energy in human skin wins Best of Basic Science and Translational Research Session Award
  • Results to be featured at the 2018 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Dallas on April 11-15, 2018

HAYWARD, Calif.--(BUSINESS WIRE)--Apr. 12, 2018-- Pulse Biosciences, Inc. (Nasdaq:PLSE) announced clinical efficacy results of its first multi-center study of Nano-Pulse Stimulation (NPS) technology for the treatment of seborrheic keratosis lesions (SKs) in humans. The findings will be featured at the 2018 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference to be held in Dallas on April 11-15, 2018. The company also will present data from the first-in-human clinical study of NPS dose-response effects. These definitive studies establish the foundation for future therapeutic applications of NPS across a range of benign and cancerous skin growths.

In the clinical trial of SK elimination using the novel, non-thermal NPS technology, seborrheic keratosis lesion reduction assessments of a single, localized SK treatment showed that 82% of 174 treated lesions were rated as clear or mostly clear after 106 days in 58 adult patients. An independent, blinded photographic review of lesion images scored 71% of lesions as clear or mostly clear. Patients rated 78% of lesion outcomes as satisfied or mostly satisfied, closely mirroring investigator ratings.

Thomas Rohrer, MD, a leading dermatologic and Mohs skin cancer surgeon in Boston, MA will present study results on Friday, April 13 at 4:37pm CST in a talk titled First Clinical Use of Non-Thermal Nano-Pulse Stimulation to Eliminate Seborrheic Keratosis Lesions. “These impressive results demonstrate the reliable removal of SK lesions with a single treatment using NPS technology,” said Dr. Rohrer. “Pulse’s NPS technology has made a significant leap from very promising pre-clinical results to its first successful application in the removal of a common benign skin lesion with consistent results observed at each of the four top medical centers participating in the study. This unique mechanism of action of non-thermal NPS shows great potential for treating a range of benign and non-benign skin lesions.”

In addition to Dr. Rohrer, other investigators in the SK trial included dermatologist George Hruza, MD, a Mohs skin cancer surgeon in St. Louis, MO; facial plastic surgeon James Newman, MD, Chief of Plastic Surgery at Premier Plastic Surgery Clinics in the San Francisco Bay Area, CA; and dermatologist Brian Zelickson, MD of Minneapolis, MN, who is widely recognized for his research in skin tissue effects related to energy-based devices.

The second publication of Pulse Biosciences research at the energy-based science and medicine conference was conferred the ASLMS Best of Basic Science and Translational Research Award. The winning paper is titled A Dose-Response Study of a Novel Non-Thermal Method of Selectively Modifying Cellular Structures in Skin with Low Energy Nanosecond Electrical Stimulation. Clinical results showed that NPS demonstrates a non-thermal mechanism for targeting cellular structures with very low-grade inflammation that does not affect the viability of the non-cellular dermal tissue across a wide range of energy levels as evaluated by clinical and histological responses observed in human skin. This research will be presented on Friday, April 13 at 10:05am CST.

According to dermatopathologist Dr. Mehregan, “Our dermatopathology lab analyzed over 200 biopsy samples from NPS-treated human skin and observed a pattern of unique cellular-effects that spared the non-cellular dermis at most energy doses. These basic tissue findings demonstrate real promise for clinical studies of multiple future clinical applications.”

Publication co-authors included plastic surgeon David Kaufman, MD, Folsom, CA; Michelle Martinez, RN, BSN, of Kaufman Plastic Surgery in Folsom, CA; Brian Zelickson, MD; David Mehregan, MD, of Detroit and Monroe MI; and Pulse Biosciences contributors Richard Nuccitelli, PhD, Edward Ebbers, and Lauren Jauregui.

“We were pleased that histology results and clinical findings from the dose response study were predictive of the high lesion clearance rates observed in our first controlled study of a seborrheic keratosis treatment,” said Ed Ebbers, Vice President and General Manager of Dermatology at Pulse Biosciences. “These impressive safety results and robust SK efficacy rates increase our confidence in future planned study treatments of other benign lesions, such as keloids and warts, and non-benign skin lesions.”

“The presentation of our initial NPS clinical data at the prestigious ASLMS annual meeting is an important milestone for our dermatology program and Pulse Biosciences, as we continue to build the evidence in support of NPS as a unique and compelling treatment modality across a number of applications,” added Darrin Uecker, President and CEO of Pulse Biosciences.

For more information: NPS study data presented at 2018 ASLMS Annual Meeting

About the SK Study

Fifty-eight (58) adult subjects in four clinical centers were required to have at least four (4) off-face lesions within study criteria for size, and a clinical diagnosis of SK. A local anesthetic was injected prior to treatment with the NPS device. Three lesions were treated in a single session, and one lesion was left untreated as a control. Subjects returned five times over a 106-day period for physician assessment of SK lesions and the cosmetic appearance of treated areas.

About Seborrheic Keratoses

Seborrheic keratosis (SK) typically appears as a raised skin lesion with a waxy, scaly texture that can vary in color from light tan to dark brown or black. It affects more than 80 million people in the United States and is often associated with aging skin. A recently published study in the Journal of Clinical and Aesthetic Dermatology found that 61% of patients took action to hide, disguise, or distract attention from their SK lesions. The published study also noted that 86% of SK sufferers were somewhat or extremely interested in a removal treatment in a dermatologist's office and willing to pay a reasonable out-of-pocket fee. Leading clinicians generally agree that the effective treatment of SK lesions with a non-surgical and nonthermal procedure represents a highly desired alternative to patient inaction due to limitations of existing treatments.

About Pulse Biosciences

Pulse Biosciences is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a non-thermal, precise, focal, drug-free tissue treatment technology utilizing nanosecond (billionth of a second) range pulsed electric fields that directly affect the cell membrane and intracellular structures and initiates programmed cell death in treated cells. The unique ability of NPS to initiate cell death has the potential to significantly benefit patients in a wide variety of medical applications including applications in immuno-oncology and dermatology, and other potential applications we may pursue in the future. The initiation of programmed cell death by NPS results in a minimal inflammatory response, which improves healing outcomes and supports the replacement of treated tissue cells with healthy tissue cells. In cancerous lesions, NPS has been shown in preclinical models to induce immunogenic cell death (ICD), which exposes the unique antigens of the treated cells to the immune system and enrolls immune system cells, such as cytotoxic T-cells to mount an adaptive immune response. Pulse Biosciences is investigating a variety of applications for its technology that exploits the technology’s unique biologic effect, including immuno-oncology and dermatology. More information is available at:

CAUTION: Pulse Biosciences’ Nano-Pulse Stimulation (NPS) is an investigational use therapy.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of FDA filings or approvals, the mechanism of action of NPS treatments, current and planned future clinical studies, other matters related to its pipeline of product candidates, future financial performance and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.


The American Society for Laser Medicine and Surgery, Inc. (ASLMS) has the ultimate responsibility for the planning, development and content of continuing education programs and presentations, including those highlighted above. Pulse Biosciences did not direct content or influence the planning or implementation of The ASLMS 38th Annual Conference. The spontaneous opinions expressed by speakers and participants during these activities belong to those individuals.

Source: Pulse Biosciences, Inc.

Brian Dow
Sr. Vice President and Chief Financial Officer
Solebury Trout
Bill Kadel
Tosk Communications
Nadine D. Tosk, 504-453-8344